Insider-Led Fund Invests $5M in Convertible Notes at Premium to Market Price

summarizeSummary

CASI Pharmaceuticals secured $5 million in convertible note financing from ETP Global III Fund L.P., led by founder Wei-Wu He, Ph.D., as part of a larger $20 million program, with a conversion price floor significantly above the current stock price.

check_boxKey Events

• New Convertible Note Issued

  ETP Global III Fund L.P. purchased a $5 million convertible note from CASI Pharmaceuticals, Inc. on February 19, 2026.

• Significant Capital Infusion

  This $5 million note represents the third tranche of a $20 million convertible note financing program, providing substantial capital to the company.

• Favorable Conversion Terms

  The convertible note has a conversion price floor of $1.00 per share, which is significantly above the current stock price of $0.3507, indicating strong investor confidence.

• Use of Proceeds

  The funds are earmarked for clinical trials in China for CID-103 and general operational expenses.

auto_awesomeAnalysis

This Schedule 13D/A reports a critical $5 million convertible note financing from ETP Global III Fund L.P., an entity associated with founder Wei-Wu He, Ph.D. This capital infusion is highly significant for CASI Pharmaceuticals, given its micro-cap status. The note's conversion price floor of $1.00 per share, which is nearly three times the current stock price of $0.3507, indicates strong investor confidence in the company's future valuation. This transaction, part of a larger $20 million financing program, provides essential funding for clinical trials in China for CID-103 and general operations, significantly extending the company's operational runway and reducing near-term liquidity concerns. The increased beneficial ownership by Dr. He and affiliated entities to 53.0% further solidifies insider commitment.